This is an excellent business model and progress that BDA has regarding the Phase 1 trials.
I would steer away from medical cultivation as this introduces costs and another complexity.
Beef up even more our medical cannabis board with global Biopharma medical cannabis experts for governance and strategic direction.
BDA should partner (similarily with Linnea) with many other global leading medical cannabis producers of unique oils, strains and complexes and move towards product development for the pharmaceutical markets for export around the world.
This business model is easier to drive forward and with initial first mover advantages in Australia can result in a successful commercial business for BDA long term.
This will transform BDA into a medical cannabis pharmaceutical commercial enterprise.
Early days but I like very much
